Treatment of primary aldosteronism.
The prevalence of primary hyperaldosteronism approaches 10% of all hypertensive patients, and besides efficient diagnostic procedures, effective treatment is of increasing importance to reverse increased morbidity and mortality. Aldosterone-producing adenoma and unilateral adrenal hyperplasia are amenable to cure by endoscopic adrenalectomy. Bilateral adrenal hyperplasia (micro- or macronodular), which comprises two-thirds of primary hyperaldosteronism, is treated primarily by mineralocorticoid receptor antagonists (starting dose 12.5-25mg/day spironolactone with titration up to 100mg/day, alternatively 50-100mg/day eplerenone). If blood pressure is not normalised by this first-line treatment, additional treatment with potassium-sparing diuretics (amiloride or triamterene) or calcium channel antagonists is necessary. The start of medication should be closely monitored by serum electrolyte and creatinine controls.
Clinical Endocrinology, Charité Campus Mitte, Charité University Medicine Berlin, Charitéplatz 1, D 10117 Berlin, Germany. marcus.quinkler@charite.de
Marcus
M
Quinkler
Paul M
PM
Stewart
D000818:Animals; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D015995:Prevalence